221 related articles for article (PubMed ID: 19883882)
21. [Current issues in erythropoietin therapy of renal anemia].
Zakar G
Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
[TBL] [Abstract][Full Text] [Related]
22. Optimization of anemia treatment in hemodialysis patients via reinforcement learning.
Escandell-Montero P; Chermisi M; Martínez-Martínez JM; Gómez-Sanchis J; Barbieri C; Soria-Olivas E; Mari F; Vila-Francés J; Stopper A; Gatti E; Martín-Guerrero JD
Artif Intell Med; 2014 Sep; 62(1):47-60. PubMed ID: 25091172
[TBL] [Abstract][Full Text] [Related]
23. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
24. Target-based Anemia Management with Erythropoiesis Stimulating Agents (Risks and Benefits Relearned) and Iron (Still More to Learn).
Stivelman JC
Semin Dial; 2017 Mar; 30(2):142-148. PubMed ID: 28083917
[TBL] [Abstract][Full Text] [Related]
25. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
26. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients.
McCarthy JT; Hocum CL; Albright RC; Rogers J; Gallaher EJ; Steensma DP; Gudgell SF; Bergstralh EJ; Dillon JC; Hickson LJ; Williams AW; Dingli D
Mayo Clin Proc; 2014 Jan; 89(1):87-94. PubMed ID: 24388026
[TBL] [Abstract][Full Text] [Related]
27. Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
Schmid H; Schiffl H; Lederer SR
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):465-70. PubMed ID: 21738032
[TBL] [Abstract][Full Text] [Related]
28. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
Pirker R
Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
[TBL] [Abstract][Full Text] [Related]
29. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
30. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
Lonnemann G; Wrenger E
Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
[TBL] [Abstract][Full Text] [Related]
31. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes.
Agarwal AK; Singh AK
Heart Fail Clin; 2010 Jul; 6(3):323-32. PubMed ID: 20630407
[TBL] [Abstract][Full Text] [Related]
32. [Role of renal anemia in progression of chronic kidney disease].
Racki S; Maleta I
Acta Med Croatica; 2009 Sep; 63 Suppl 1():33-7. PubMed ID: 20235353
[TBL] [Abstract][Full Text] [Related]
33. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
[TBL] [Abstract][Full Text] [Related]
35. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of anemia in patients with chronic renal disease: is it time for self-criticism?].
Del Vecchio L
G Ital Nefrol; 2007; 24(4):285. PubMed ID: 17659497
[No Abstract] [Full Text] [Related]
37. Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2012 Nov; 11(6):923-31. PubMed ID: 22916722
[TBL] [Abstract][Full Text] [Related]
38. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
39. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
40. Erythropoiesis-stimulating agents for the management of anemia of chronic kidney disease: past advancements and current innovations.
Dutka P
Nephrol Nurs J; 2012; 39(6):447-57. PubMed ID: 23469411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
